Примери за използване на Alogliptin на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Each 12.5 mg/850 mg film-coated tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin
Each tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin
Vipidia 12.5 mg film-coated tablets Each tablet contains alogliptin benzoate equivalent to 12.5 mg alogliptin. .
In the alogliptin group, 11.3% of patients experienced a MACE compared to 11.8% of patients in the placebo group.
Nonfatal Stroke*Overall there were 153 subjects(5.7%) in the alogliptin group and 173 subjects(6.5%)
Results from alogliptin studies with metformin,
Each 25 mg/45 mg film-coated tablet contains alogliptin benzoate and pioglitazone hydrochloride equivalent to 25 mg alogliptin
Each tablet contains alogliptin benzoate and pioglitazone hydrochloride equivalent to 12.5 mg alogliptin
There was no change in the time to peak plasma concentration(Tmax) for alogliptin, but there was a delayed Tmax for metformin of 1.5 hours.
consider discontinuation of alogliptin treatment.
25 mg alogliptin and 45 mg pioglitazone)
These studies evaluated the effects of co-administered alogliptin and metformin on glycaemic control
Experience of alogliptin use in clinical studies in patients with congestive heart failure of New York Heart Association(NYHA)
In addition, Incresync can be used to replace separate tablets of alogliptin and pioglitazone in those adult patients aged 18 years
In the alogliptin group, 12.7%(344 subjects)
co-administered alogliptin plus pioglitazone should not be used in such patients(see sections 4.2 and 5.2).
These studies evaluated the effects of co-administered alogliptin and pioglitazone on glycaemic control
5- to 6-fold the maximum recommended human dose for alogliptin and metformin, respectively).
appropriate assessment of renal function is recommended prior to initiation of alogliptin therapy and periodically thereafter(see section 4.2).
12.5 mg intravenous infusion of alogliptin to healthy subjects, the volume of distribution during the terminal phase was 417 L, indicating that the drug is well distributed into tissues.